Compare Align Technology, Inc. (ALGN) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Align Technology, Inc. vs Charles River Laboratories Intl. Inc — how do they compare? Align Technology, Inc. trades at $173.38 (market cap $12.29B), while Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B). The key difference: Align Technology, Inc. and Charles River Laboratories Intl. Inc are close in size by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Align Technology, Inc. nearer its low. Which is the better fit depends on your goals.
| ALGN | CRL | |
|---|---|---|
Market Cap | $12.29B | $13.46B |
Sector | Health | Health |
52-Week High | $197.51 | $282.00 |
52-Week Low | $124.88 | $145.57 |
Enterprise Value | $11.30B | $16.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $174.63, down 0.8% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with record revenue and clear aligner volume. Fundamentals show solid profitability with a 68.05% gross margin and 9.99% net income margin, though revenue growth has moderated. Recent news highlights a patent win in China and strategic initiatives following activist investor engagement.
The outlook is mixed: analyst consensus is strongly bullish (73% buy ratings), but technicals and slowing revenue growth pose near-term risks. Investment opportunity lies in international expansion and digital dentistry platform growth, while risks include competitive pressures and execution of new strategic initiatives. The stock's valuation at 30x P/E requires sustained earnings growth to justify.
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
